Radiopharm Theranostics (ASX:RAD) Quick Ratio: 2.67 (As of Jun. 2025) — 34% Above Median


What is Radiopharm Theranostics Quick Ratio?

Radiopharm Theranostics ASX:RAD -5.00% Quick Ratio is 2.67 as of Jun. 2025, which is 34% above its 10-year median of 1.99. The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Radiopharm Theranostics ranks worse than 58.86% on this metric.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Radiopharm Theranostics's quick ratio for the quarter that ended in Jun. 2025 was 2.67.

Radiopharm Theranostics has a quick ratio of 2.67. It generally indicates good short-term financial strength.

The historical rank and industry rank for Radiopharm Theranostics's Quick Ratio or its related term are showing as below:

ASX:RAD' s Quick Ratio Range Over the Past 10 Years
Min: 1.23   Med: 1.99   Max: 3.46
Current: 2.67

During the past 4 years, Radiopharm Theranostics's highest Quick Ratio was 3.46. The lowest was 1.23. And the median was 1.99.

ASX:RAD's Quick Ratio is ranked worse than
58.86% of 1417 companies
in the Biotechnology industry
Industry Median: 3.6 vs ASX:RAD: 2.67

Radiopharm Theranostics  (ASX:RAD) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Radiopharm Theranostics Quick Ratio Related Terms


Radiopharm Theranostics Quick Ratio Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Quick Ratio Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Quick Ratio
3.46 1.23 1.30 2.67

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Quick Ratio Get a 7-Day Free Trial 1.23 0.50 1.30 3.37 2.67

ASX:RAD vs VRTX, REGN, ALNY: Quick Ratio Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics Quick Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Quick Ratio falls into.



Radiopharm Theranostics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Radiopharm Theranostics's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Quick Ratio (A: Jun. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(39.854-0)/14.933
=2.67

Radiopharm Theranostics's Quick Ratio for the quarter that ended in Jun. 2025 is calculated as

Quick Ratio (Q: Jun. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(39.854-0)/14.933
=2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 2.67 mean?
Radiopharm Theranostics (ASX:RAD) has a Quick Ratio of 2.67 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Radiopharm Theranostics and its competitors. This is 34% above median its historical median of 1.99. Over the past decade, Radiopharm Theranostics' Quick Ratio has ranged from 1.23 to 3.46. According to the industry distribution chart, Radiopharm Theranostics ranks #834 out of 1417 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Radiopharm Theranostics' Quick Ratio too high?
Radiopharm Theranostics' current Quick Ratio of 2.67 is 34% above median its 10-year median of 1.99. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 3.46. The Biotechnology industry median Quick Ratio is 3.60. Radiopharm Theranostics' value of 2.67 is 25.8% below this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #834 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint.
How does Radiopharm Theranostics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #834 out of 1417 companies for Quick Ratio. This places Radiopharm Theranostics in the lower half of its industry. The industry median Quick Ratio is 3.60. Radiopharm Theranostics' value of 2.67 is 25.8% below this benchmark. Historically, Radiopharm Theranostics' own Quick Ratio has ranged from 1.23 to 3.46 over the past decade. While the company's 10-year median is 1.99 vs. the industry median of 3.60, Radiopharm Theranostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Quick Ratio of 2.67 is 25.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Quick Ratio is 2.67, which is 34% above median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Quick Ratio of 2.67. The current Quick Ratio is 2.67, which is 34% above median its 10-year median of 1.99 and 25.8% below the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Quick Ratio is 2.67 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.